PUBLISHER: TechNavio | PRODUCT CODE: 1911019
PUBLISHER: TechNavio | PRODUCT CODE: 1911019
The global duchenne muscular dystrophy (dmd) therapeutics market is forecasted to grow by USD 7030.1 mn during 2025-2030, accelerating at a CAGR of 29.4% during the forecast period. The report on the global duchenne muscular dystrophy (dmd) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by commercialization and label expansion of gene therapies, approval of novel non-steroidal and histone deacetylase inhibitors, strategic global partnerships and regulatory progress.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2026 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 25.6% |
| CAGR | 29.4% |
| Incremental Value | $7030.1 mn |
Technavio's global duchenne muscular dystrophy (dmd) therapeutics market is segmented as below:
By Type
By Distribution Channel
By Product Type
Geography
This study identifies the expansion of dissociative steroid therapies as one of the prime reasons driving the global duchenne muscular dystrophy (dmd) therapeutics market growth during the next few years. Also, advancement of peptide-conjugated oligonucleotide delivery systems and regulatory trends and innovative treatment adoption will lead to sizable demand in the market.
The report on the global duchenne muscular dystrophy (dmd) therapeutics market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global duchenne muscular dystrophy (dmd) therapeutics market vendors that include Akashi Therapeutics, Inc., Avidity Biosciences, Inc., BioMarin Pharmaceutical Inc., Capricor Therapeutics Inc., Editas Medicine, Inc., F. Hoffmann La Roche Ltd., FibroGen Inc., Italfarmaco Holding SPA, MeiraGTx Holdings Plc., NS Pharma, Inc., Precision BioSciences, Inc., PTC Therapeutics Inc., ReveraGen BioPharma, Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc, Wave Life Sciences Ltd.. Also, the global duchenne muscular dystrophy (dmd) therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.